How does SLNO's EPS stability affect short-term trades?

**Soleno Therapeutics' (SLNO) EPS stability does not significantly affect short-term trades**, as evidenced by the following points: 1. **Recent Surge in Stock Price**: SLNO's stock has experienced a significant surge, with a nearly 50% increase in trading on the morning of the FDA approval announcement. This suggests that investor sentiment is primarily driven by the approval of Vykat rather than EPS stability. 2. **Analyst Optimism and Price Target Increases**: Analysts have set price targets as high as $108, with Stifel projecting peak revenues from Vykat could reach $1.5 - $2 billion. This positive outlook is likely due to the drug's market potential rather than EPS stability. 3. **Institutional Investor Activity**: Institutional investors have shown interest in SLNO, with TD Asset Management Inc increasing its position in the company. This suggests that the company's potential for growth and the FDA approval are more important to institutional investors than EPS stability. 4. **Market Focus on Commercial Launch**: The focus is more on the commercial launch of Vykat and its potential market impact rather than EPS stability. The company's readiness to finalize the expansion of its sales force and the anticipated demand for the drug indicate that the market is more interested in these factors than EPS stability. In conclusion, while EPS stability is important for long-term investment decisions, it does not appear to be a significant factor in short-term trades for SLNO. The market's focus is more on the FDA approval of Vykat and its potential market impact, which could lead to further stock price appreciation in the short term.